15 August 2011
A natural compound has been proven to help slow the growth of prostate cancer, interdisciplinary research in Sweden has uncovered.
The compound galiellalactone was previously known to affect a protein prevalent in the stem cell-like prostate cancer cells, known as STAT3, but the studies have since proven its inhibitory effects.
Chemotherapy treatment is often of varying use in the treatment of prostate cancer, according to the researchers from Lund University and Skaane University Hospital in Malmo published online in PLoS ONE.
"The cancer stem cells are often unresponsive to both hormonal treatment and to chemotherapy, so it is essential to develop a direct treatment towards all types of cancer cells," explained Professor Anders Bjartell at Skaane.
It is now thought the research will inform further clinical tests into the effectiveness of galiellalactone for future prostate cancer treatments.
Meanwhile, studies in the Journal of Urology have illustrated how current pre and postoperative counselling for men dealing with the disease is inadequate, with nearly 50 per cent of males expecting unrealistic results from treatment.
Posted by Philip Briggs
1 Bjartell, Anders, "Galiellalactone Inhibits Stem Cell-Like ALDH-Positive Prostate Cancer Cells". PLoS ONE. Friday August 12th 2011.
2 Wittmann, Daniela, Chang He, et al., "Patient Preoperative Expectations of Urinary, Bowel, Hormonal and Sexual Functioning Do Not Match Actual Outcomes 1 Year After Radical Prostatectomy". Journal of Urology. Monday August 8th 2011.
Health News is provided by Adfero in collaboration with Spire Healthcare. Please note that all copy above is ©Adfero Ltd. and does not reflect views or opinions of Spire Healthcare unless explicitly stated. Additional comments on the page from individual Spire consultants do not necessarily reflect the views or opinions of other consultants or Spire Healthcare.